Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01139190 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults
A Phase 2 study, sponsored by PLx Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT01139190 is a Phase 2 study that has completed, run by PLx Pharma. The registered enrollment target is 77 participants.
The verdict
NCT01139190, a Phase 2 study, has completed, sponsored by PLx Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the subchronic gastrointestinal (GI) safety of PL3100 versus Naproxen in normal healthy volunteers.
Interventions
- DRUG Naproxen
- DRUG PL3100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2010-07 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01139190
The ClinicalTrials.gov registry entry for NCT01139190 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PLx Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Naproxen is the first listed.
NCT01139190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01139190 about?
NCT01139190 is a clinical study titled "Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults". The purpose of this study is to determine the subchronic gastrointestinal (GI) safety of PL3100 versus Naproxen in normal healthy volunteers.
What is the current status of trial NCT01139190?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2010-07. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01139190?
The interventions under investigation include: Naproxen (DRUG), PL3100 (DRUG).
Who is sponsoring clinical trial NCT01139190?
This trial is sponsored by PLx Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.